January 5

FDA May Relassify ECT devices

If you are concerned about the possibility that the FDA may exempt manufacturers of electroconvulsive therapy (ECT) devices from the regulatory requirement to prove their devices safe and effective through the PreMarket Approval (PMA) process, tomorrow, Jan. 8th is your last chance to send in your comments:

The identification of the proposed rule change is: FDA-2009-N-0392 You can post comments at:

or call: 1-877-378-5457 (very helpful staff)

or email: regulations.gov_helpdesk@bah.com

This is a very contentious proposition advocated by–needless to say–manufacturers of ECT devices and a powerful cadre of psychiatrists who are financially invested in the business of ECT.

The issue is about safety and honest disclosure about the documented and potential risk of harm–primarily memory loss following electroshock.

There is a large backlog in the posting of comments received by the FDA about this issue–

See AHRP public comments submitted to the FDA: Click here for full article


Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.


You may also like

September 5, 2023

Part 5. COVID Vaccines: The Chicken or the Egg? The health authorities could have just been ignorant—that

Read More
Part 5. COVID Vaccines: The Chicken or the Egg? (From “The WHO’s Proposed Treaty Will Increase Man-Made Pandemics”)

September 5, 2023

Part 4. Maiming with Myocarditis Both of the two US monkeypox/smallpox vaccines (Jynneos and ACAM2000) are known

Read More
Part 4. Maiming with Myocarditis (From “The WHO’s Proposed Treaty Will Increase Man-Made Pandemics”)